Skip to main content
Top
Published in: Endocrine 3/2024

22-09-2023 | COVID-19 | Original Article

Abdominal adipose tissue distribution assessed by computed tomography and mortality in hospitalised patients with COVID-19: a retrospective longitudinal cohort study

Authors: Sofia Battisti, Claudio Pedone, Flavia Tramontana, Nicola Napoli, Ghadeer Alhamar, Emanuele Russo, Vanni Agnoletti, Elisa Paolucci, Mario Galgani, Emanuela Giampalma, Annalisa Paviglianiti, Rocky Strollo

Published in: Endocrine | Issue 3/2024

Login to get access

Abstract

Background

Visceral adiposity has been associated with an increased risk of critical illness in COVID-19 patients. However, if it also associates to a poor survival is still not well established. The aim of the study was to assess the relationship between abdominal fat distribution and COVID-19 mortality.

Methods

In this six-month longitudinal cohort study, abdominal visceral (VAT) and subcutaneous adipose tissues (SAT) were measured by computed tomography in a cohort of 174 patients admitted to the emergency department with a diagnosis of COVID-19, during the first wave of pandemic. The primary exposure and outcome measures were VAT and SAT at hospital admission, and death at 30 and 180 days, respectively.

Results

Overall survival was not different according to VAT (p = 0.94), SAT (p = 0.32) and VAT/SAT ratio (p = 0.64). However, patients in the lowest SAT quartile (thickness ≤ 11.25 mm) had a significantly reduced survival compared to those with thicker SAT (77 vs. 94% at day 30; 74 vs. 91% at day 180, p = 0.01). Similarly, a thinner SAT was associated with lower survival in Intensive Care Unit (ICU) admitted patients, independently of sex or age (p = 0.02). The VAT/SAT ratio showed a non-linear increased risk of ICU admission, which plateaued out and tended for inversion at values greater than 1.9 (p = 0.001), although was not associated with increased mortality rate.

Conclusions:

In our cohort, visceral adiposity did not increase mortality in patients with COVID-19, but low SAT may be associated with poor survival.
Appendix
Available only for authorised users
Literature
19.
go back to reference F.E.L. Beltrao, D.C.A. Beltrao, G. Carvalhal et al. (2022) Low muscle mass and high visceral fat mass predict mortality in patients hospitalized with moderate-to-severe COVID-19: a prospective study. Endocr Connect 11(10). https://doi.org/10.1530/EC-22-0290 F.E.L. Beltrao, D.C.A. Beltrao, G. Carvalhal et al. (2022) Low muscle mass and high visceral fat mass predict mortality in patients hospitalized with moderate-to-severe COVID-19: a prospective study. Endocr Connect 11(10). https://​doi.​org/​10.​1530/​EC-22-0290
20.
31.
Metadata
Title
Abdominal adipose tissue distribution assessed by computed tomography and mortality in hospitalised patients with COVID-19: a retrospective longitudinal cohort study
Authors
Sofia Battisti
Claudio Pedone
Flavia Tramontana
Nicola Napoli
Ghadeer Alhamar
Emanuele Russo
Vanni Agnoletti
Elisa Paolucci
Mario Galgani
Emanuela Giampalma
Annalisa Paviglianiti
Rocky Strollo
Publication date
22-09-2023
Publisher
Springer US
Published in
Endocrine / Issue 3/2024
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-023-03530-4

Other articles of this Issue 3/2024

Endocrine 3/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Webinar | 06-02-2024 | 20:00 (CET)

Mastering chronic pancreatitis pain: A multidisciplinary approach and practical solutions

Severe pain is the most common symptom of chronic pancreatitis. In this webinar, experts share the latest insights in pain management for chronic pancreatitis patients. Experts from a range of disciplines discuss pertinent cases and provide practical suggestions for use within clinical practice.

Sponsored by: Viatris

Developed by: Springer Healthcare